LDLRAP1-IN-1 (Compound B19) is a LDLRAP1 inhibitor and antiviral agent, with an IC50 of 4.98 μM for disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 covalently modifies the C119 residue of LDLRAP1 at the LDLRAP1-LDLR binding interface, thereby disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 exhibits antiviral activity against HCoV-OC43.

LDH-IN-5 is a Lactate Dehydrogenase (LDH) inhibitor with neuroprotective activity. LDH-IN-5 can inhibit cell apoptosis, reduce ROS, MDA production and increases superoxide dismutase (SOD) activity. LDH-IN-5 can be used for the research of neurological disease, such as ischemic stroke.

LCK ligand-1 is a ligand targeting LCK, which serves as a target protein ligand for the synthesis of the PROTAC degrader SJ45566.

LCK degrader-3 (Compound 20) is a CRBN-based LCK molecular glue degrader. LCK degrader-3 can be used in the research of acute lymphoblastic leukemia.

LCI133 is afirst-in-class,nanomolar-potent, selective multikinase inhibitor targeting CDK4/6/9 and AURKA/B (IC50 = 4.7/10.2/4.1 nM and 2.8/10.6 nM). LCI133 induces S/G2 cell-cycle arrest and robust apoptosis in MYCN-amplified neuroblastoma BE(2)-C cells. LCI133 demonstrates significant antitumor efficacy in a BE(2)-C neuroblastoma xenograft model.

LCB-2183 is an orally active antiallergic agent. LCB-2183 can inhibit tracheal hyperreactivity and pulmonary inflammation in mouse airways.

LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin-induced cardiomyocytes apoptosis with an IC50 of 0.5 μM and prevent Imatinib-induced apoptosis. LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase (ACC). LCB-2122 can reduce Doxorubicin-induced mitochondrial damage. LCB-2122 can be used for the research of heart failure.

LC-61 is a potent antileishmanial agent with an IC50 of 0.076 µM against intracellular L. infantum.

Lazertinib (YH25448; GNS-1480) mesylate hydrate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate hydrate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate hydrate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate hydrate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate hydrate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia.

LASSBio-2389 is a selective ROCK2 inhibitor with an IC50 of 0.051 μM and an IC50 of 1.143 μM against ROCK1. LASSBio-2389 reduces the viability of MDA-MB-231 cells and inhibits cell migration. LASSBio-2389 is applicable to the research of triple-negative breast cancer.

LasB-IN-3 is a protease elastase (LasB) inhibitor of Pseudomonas aeruginosa with an IC50 value of 8.5 nM. LasB-IN-3 shows an IC50 of 58.9 nM for the Met128Val mutant. LasB-IN-3 binds to active sites of wild-type and Met128Val mutant LasB, coordinates zinc ions, forms hydrogen bonds and CH-π interactions, and inhibits LasB proteolytic activity. LasB-IN-3 increases survival rate in LasB-induced acute lung injury mice models. LasB-IN-3 can be used for the research of Pseudomonas aeruginosa infection.

L-Arg-DSPE is an arginine-functionalized DSPE lipid containing free guanidine groups. L-Arg-DSPE serves as a component of NO-responsive degradable drug-loaded liposomal nanomotors (L-Arg@Lip-DOX), promoting drug deep tumor tissue penetration and cellular internalization. L-Arg-DSPE can be used for the research of drug delivery.

Largazole thiol, the active form of Largazole, is a potent, selective and brain-penetrant class I HDAC inhibitor. Largazole thiol. Largazole thiol exerts antitumor and neuroprotective effects. Largazole thiol can be used for research of Glioblastoma.

Lantadene B is a triterpene component. Lantadene B can be isolated from the red variety of Lantana Camara. Lantadene B can be used in the research of cancer and inflammatory diseases.

Lanopepden camsylate (GSK1322322 camsylate) is a high-affinity bacterial peptide deformylase inhibitor. Lanopepden camsylate is applicable to research related to bacterial infections.

Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA.

L-797591 hydrochloride is a selective sst1 agonist. L-797591 hydrochloride mimicks the effects of SRIF-14 and SRIF-28 by potently inhibiting either Forskolin-stimulated or CRH-stimulated cAMP accumulation.

L-652343 is a dual cyclooxygenase/lipoxygenase inhibitor. L-652343 can inhibit the production of LTB4 in isolated human polymorphonuclear leukocytes treated with Calcimycin (IC50: 1.4 μM), but it is inactive in whole blood. L-652343 can be used in the research of inflammatory and immune diseases.

L-4-Aminoarabinose-bactoprenyl phosphate (L-4-Aminoarabinose-BP) is a substrate of the ArnT enzyme and participates in lipid A modification through covalent bonding. L-4-Aminoarabinose-bactoprenyl phosphate transfers L-4-aminoarabinose (Ara4N) to the lipid A portion of lipopolysaccharide (LPS), mediating cationic modification of lipid A, thereby conferring resistance to cationic antimicrobial peptides (CAMPs) in Gram-negative bacteria. L-4-Aminoarabinose-bactoprenyl phosphate is an endogenous intermediate synthesized in vivo by a series of enzymes such as ArnC and ArnD encoded by the arn operon in Gram-negative bacteria such as Escherichia coli.

L-367773 is an orally active, selective oxytocin receptor antagonist, with Ki values of 26 nM and 61 nM for rat uterine oxytocin receptor and human uterine oxytocin receptor, respectively. L-367773 inhibits Oxytocin-stimulated uterine contractions.

L-163958 is an efficient, orally active, balanced angiotensin II receptor (AII receptor) antagonist. L-163958 has balanced high affinity for AT1 and AT2, with its IC50 values being 0.16, 0.12, 0.50, and 0.64 nM in rabbit aorta (AT1), rat midbrain (AT2), human adrenal gland (AT1), and human adrenal gland (AT2), respectively. L-163958 has a strong inhibitory effect on the pressor activity in rats. L-163958 can be used for the study of hypertension and related cardiovascular diseases.

KY0418 is a selective GPX4 inhibitor. KY0418 selectively and covalently modifies the selenocysteine residue of GPX4 and inhibits GPX4 activity. KY0418 induces ferroptosis and suppresses cell proliferation. KY0418 can be used for the study of ferroptosis and cancer.

KW-2170 hydrochloride is an alkylating agent and topoisomerase II inhibitor. KW-2170 hydrochloride stabilizes the topoisomerase II-DNA complex, causing DNA double-strand breaks, thereby preventing DNA replication and transcription, and ultimately leading to the death of tumor cells. KW-2170 hydrochloride exhibits potent and broad-spectrum anti-tumor activity in various mouse and human tumor models. KW-2170 hydrochloride can be used in the research of solid tumors.

Kv7.2/Kv7.3 modulator-3 (example 40 peak-1) is a selective Kv7.2/Kv7.3 modulator with an EC50 of 0.099 μM.

KV1.3-IN-2 hydrochloride is a kv1.3 potassium channel inhibitor without affecting hERG channel activity. KV1.3-IN-2 hydrochloride can be used in research of immune-related diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus.

KTT-1 is a kinetically selective and orally active HDAC2 inhibitor. KTT-1 exhibits high HDAC2-selectivity over HDAC1. KTT-1 inhibits osteoclast differentiation at an early stage by downregulating c-Fos expression. KTT-1 effectively suppresses arthritis symptoms in the collagen-induced arthritis (CIA) mouse model. KTT-1 can be used for the research of rheumatoid arthritis and neurodegenerative diseases.

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups.

KSP-IN-2 (compound 12) is a kinesin spindle protein (KSP) inhibitor with an IC50 of 450 nM.

KSP-1007 is a bicyclic boronate-based broad-spectrum β-lactamase inhibitor. KSP-1007 can effectively inhibit class A, B, C and D β-lactamases, including serine-type, metallo-type (such as NDM, VIM, IMP) and Acinetobacter baumannii OXA-type enzymes. KSP-1007 can enhance the antibacterial activity of Meropenem, reduce its MIC value, and be effective against carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. KSP-1007 can be used for the research of bacterial infection.

KS 501 is a potent and selective calmodulin inhibitor. KS 501 inhibits the activation of calmodulin kinase I and II, but has less effect against cyclic adenosine 3’,5’-monophosphate (cyclic AMP)-sensitive kinase. KS 501 inhibits the enzyme through interfering with calmodulin activation rather than through a direct effect on the enzyme. KS 501 can be used for the study of leukemia.